Moderna Therapeutics Inc. (Cambridge, Mass.) and Merck & Co. Inc.(NYSE:MRK) partnered to develop and commercialize mRNA-based cancer vaccines that encode patient-specific neoantigens. Merck
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury